In Jewish men from 1990 to 2007, and in Jewish women in 2006, the incidence of colorectal cancer has been kept stable. Later on, a distinct decrease was seen in both sexes. In Arab men from 1990 to 2005 and in Arab women in 2007, an increase in colorectal cancer incidence occurred. Later on, the men kept stable, while the women distinctly decreased. In analyzing the trends according to age groups, it was found that it the last decade, the younger group (20-44) showed a rise in incidence mainly among women (Jewish and Arab) as well as in Arab men. However, it is important to note that the 20-44 age group represents an addition of less than five cases per year. The remaining age groups showed a decrease:
The young group (20-44) in the last decade: in Jews, the incidence was stable in men, but in women there was a decrease since 2009. In Arabs, there was a rise both in men and in women. As said, it is important to note that the 20-44 age group represents an addition of less than five cases per year.
The intermediate age group (45-64) in the last decade: this group includes some of the target population for the national colorectal screening program. In both Jewish men (since 2013) and women, a distinct decrease was shown in morbidity rates. In Arabs men and women, a distinct decrease was shown in morbidity since 2006.
The older age group (65+) in the last decade: in Jewish men (since 2006) and women (since 2005), a distinct decrease in incidence was shown. In Arab men (since 2006) and women (since 2008), a distinct decrease in incidence was shown.
For over a decade, the ICA has adopted World Health Organization and the Union for International Cancer Control (UICC) guidelines regarding the importance of screening populations at high risk for colorectal cancer. This education program focuses on the general public within the community and in the workplace.
Aiming to promote early detection awareness and raise the test compliance rate, the ICA annually finances two years of targeted activity at centers that have demonstrated outstanding work in screening programs for high-risk populations, while conducting training activity for professional staff and educational programs for the general public.
Normal risk population (symptom-free and no family background) – every individual over the age of 50 should undergo a fecal occult blood test once a year. High risk patients are entitled to a colonoscopy examination covered by their healthcare fund.
Population with colorectal cancer family history (first of second degree relative or two second-degree relatives) – should undergo colonoscopy from the age of 40, or 10 years prior to the diagnosis age of the relative. If the examination result is normal, 5-year follow-up examinations should be taken, or according to the primary physician’s recommendations.
Population diagnosed with colorectal cancer – are advised to be checked for a possible detection of Lynch syndrome, which is vital information for their first-degree relatives.
Population with increased family background – that is, multiple cases of colorectal or uterus malignancy in the family, at a young age, or when the existence of Lynch syndrome or familial adenomatous polyposis (FAP) or suspected existence are known – to see any one of the early detection clinics for further inquiry.
Population with other risk factors, such as an inflammatory bowel disease, past colon polyps or relatives with polyps – must consult a physician regarding the age and frequency in which colonoscopy should be performed.
Israel Cancer Association experts recommend paying attention to symptoms and changes in the body which may indicate the existence of colorectal cancer. It is important to know that colorectal cancer may not cause al of the following symptoms, but even just one of them:
The appearance of any one of these symptoms requires immediately attention by you a family physician. In such cases, the physician may consider referring to a colonoscopy examination. Fecal occult blood test are not meant for people who complain of such symptoms, but for people who are symptom-free, as part of the national screening program.